Actively Recruiting
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
Led by M.D. Anderson Cancer Center · Updated on 2026-03-20
10
Participants Needed
1
Research Sites
263 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This early phase I trial examines the safety and effects of fecal microbial transplants in treating patients with pancreatic cancer. scheduled for surgery to remove tumors. Fecal microbial transplant contains the normal microbes found in fecal (stool) material. Giving fecal microbial transplant may help control the disease.
CONDITIONS
Official Title
Fecal Microbial Transplants for the Treatment of Pancreatic Cancer
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients seen at MD Anderson Cancer Center
- Diagnosed with pancreatic ductal adenocarcinoma expected to undergo surgery (Whipple procedure)
- Adequate white blood cell count (≥ 3,000/microL), platelet count (≥ 75,000/microL), and hemoglobin (≥ 8 g/dL)
- Adequate liver function with total bilirubin ≤ 1.5 times upper limit of normal, AST ≤ 2.5 times upper limit of normal, and ALT ≤ 2.5 times upper limit of normal
- Adequate kidney function with creatinine clearance > 30 mL/min
- Age 18 years or older
- Male or female
- Willingness and ability to sign informed consent
- Ability to provide blood and stool samples
- Consent to baseline tumor biopsy and colonoscopy for FMT delivery
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
You will not qualify if you...
- Younger than 18 years old
- Positive gastrointestinal infection
- Pancreatic cancer staged as T1N0
- Higher risk for colonization with multidrug-resistant organisms (MDROs)
- Received antibiotics within the last 48 hours (eligible if antibiotics stopped at least 48 hours before study start)
- Active viral, bacterial, or fungal infection
- History of inflammatory bowel disease, radiation enteritis, or colitis
- Pregnant or breastfeeding women
- Women of child-bearing potential with positive or refused pregnancy test
- Diagnosis of immunodeficiency
- White blood cell count > 12 x 10^9/L or temperature > 38°C
- Neutropenia (absolute neutrophil count < 1500)
- Swallowing dysfunction or chronic aspiration
- Delayed gastric emptying
- History of intestinal obstruction
- Acute worsening of other medical conditions
- Severely immunocompromised
- Allergies to any drugs used in the trial (antibiotics, loperamide, laxatives)
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
M D Anderson Cancer Center
Houston, Texas, United States, 77030
Actively Recruiting
Research Team
F
Florencia McAllister, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here